Horwitz SM, Feldman TA, Ye JC, Khodadoust MS, et al. Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma. Leuk Lymphoma 2025 Feb 8:1-11. doi: 10.1080/10428194.2025.2455489.
PMID: 39921522